A new ASTRO clinical guideline recommends moderately shortened radiation schedules for all risk groups of localized prostate ...

A new clinical guideline from the American Society for Radiation Oncology (ASTRO) recommends shorter courses of radiation ...

The update replaces ASTRO’s 2018 recommendations to reflect the growing body of evidence showing that hypofractionated ...

A national study of more than 20,000 men with localized prostate cancer found that surgery was linked to higher rates of urinary incontinence and erectile dysfunction, while radiation therapy was ...

University Hospitals research suggests the Decipher tumor score could help doctors personalize treatment decisions for men ...

Prostate cancer is Australia's most commonly diagnosed cancer. One in six men will be diagnosed by the time they turn 85. Cancers are abnormal groups of cells that grow uncontrollably and start ...

For many men with prostate cancer, weeks of daily treatments are no longer the norm. Jonathan Tward, MD, a radiation oncologist at Huntsman Cancer Institute, explains how image guidance, real-time ...

Three phase 3 prostate cancer results from ESMO 2026 cover long-term survival with abiraterone in metastatic disease, Erleada before and after surgery, and an update on Truqap for PTEN-deficient ...

Brachytherapy and proton therapy are radiation therapies, while HIFU and TULSA are focal therapies with distinct mechanisms. Medicare typically covers HIFU but not TULSA, with potential future ...

Over the last 15 years, low-risk prostate cancer has become less common at diagnosis and is increasingly managed through active surveillance, according to research published in Ca ...

Parul N. Barry, MD, FACRO, discussed extending advanced radiation services to satellite sites and offered guidance for early career physicians building new programs.

An updated clinical guideline from the American Society for Radiation Oncology (ASTRO) provides evidence-based ...